Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally admin...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 12; no. 1; p. 2295
Main Authors Rosenke, Kyle, Hansen, Frederick, Schwarz, Benjamin, Feldmann, Friederike, Haddock, Elaine, Rosenke, Rebecca, Barbian, Kent, Meade-White, Kimberly, Okumura, Atsushi, Leventhal, Shanna, Hawman, David W., Ricotta, Emily, Bosio, Catharine M., Martens, Craig, Saturday, Greg, Feldmann, Heinz, Jarvis, Michael A.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 16.04.2021
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…